CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

EarningsXDEMVY®Positive
AI Analysis

Summary

Tarsus reported Q1 2026 net product sales of more than $145 million for XDEMVY®, representing an 85% year-over-year increase.

Financial Highlights

Revenue

$145 million

Importance:5/10
Sentiment:
0.70
Q1 2026 earningsproduct salesXDEMVY
Related Companies

Read the original article

Published by GlobeNewswire Pharma on May 6, 2026 8:05 PM

Read Original